|
Mar 4
|
Viatris' (VTRS) Generic Declines in Q4, Yupleri Sales Rise
|
|
Jan 25
|
Here’s Why Greenlight Decided to Repurchase Viatris (VTRS)
|
|
Jan 22
|
12 S&P 500 Stocks On the Move
|
|
Jan 14
|
These 9 Stocks Are Running To Start 2024
|
|
Jan 11
|
Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now
|
|
Dec 27
|
Regeneron Gains After Eye-Drug Patent Victory Over Viatris
|
|
Dec 21
|
Viatris to Participate in 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 7
|
Viatris (VTRS) Up 5.1% Since Last Earnings Report: Can It Continue?
|
|
Nov 17
|
Top 30 Lowest P/E Ratios of the S&P 500
|
|
Nov 17
|
Why the Cheapest Stock in the S&P 500 Is No Bargain
|
|
Nov 14
|
Viatris to Participate in the Jefferies London Healthcare Conference
|
|
Nov 13
|
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
|
|
Nov 9
|
Top 20 Drug Companies in the US by Revenue
|
|
Nov 9
|
The Viatris Inc (VTRS) Company: A Short SWOT Analysis
|
|
Nov 8
|
Viatris Inc. (NASDAQ:VTRS) Q3 2023 Earnings Call Transcript
|
|
Nov 8
|
Viatris (VTRS) Q3 Earnings Beat, Complex Generics Sales Dip
|
|
Nov 8
|
Theravance's (TBPH) Q3 Loss Narrows, Revenues Beat Marginally
|
|
Nov 7
|
Viatris (VTRS) Beats Q3 Earnings Estimates
|
|
Nov 7
|
Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1]
|
|
Nov 6
|
Should You Buy Viatris (VTRS) Ahead of Earnings?
|